Ophthalmoplegia Market Research Report- Forecast Till 2027

Ophthalmoplegia Market Information: By Types (External Opthalmoplegia, Internuclear Opthalmoplegia), By Treatment (Surgery, Drug Treatment), By End Users (Hospital & Clinics, Ambulatory Clinics) - Forecast Till 2027

ID: MRFR/Pharma/2872-HCR | February 2021 | Region: Global | 80 pages

Ophthalmoplegia Market Scenario 

Ophthalmoplegia, also referred as extra ocular muscle palsy, is a paralysis of the extra ocular muscles that control movements of eyes. In this condition, nerve fibers that coordinate both eyes in horizontal movements looking from side to side- are damaged. A number of devices and treatments are available in the market, which can cure or improve the eyesight of the patient. The Global ophthalmoplegia market is driven by increasing number of people with ophthalmoplegia and increasing geriatric population. According to the World Health Organization in 2010, about 250 million people of over 50 years were suffering from visual impairment. Around 80% people in many of the developing countries have eye sight problems; of which nearly 50% of the people are not able to take treatment due to huge cost of the surgeries. Increasing prevalence of eye sight affecting diseases, for instance, diabetes and rapid developments in technology have fuelled the growth of the market. On the other hand, high cost of the treatment and availability of cheap alternative treatment may slow the growth of the market. The ophthalmoplegia market is expected to grow at a CAGR of ~ 7.2 % during the forecast period 2017-2023.

Figure: Global Ophthalmoplegia Market by Treatment Market Share, 2016 (%) Ophthalmoplegia Market


The global ophthalmoplegia market has been segmented on the basis of type, treatment and end user.

On the basis of types, the market is segmented into external ophthalmoplegia and internuclear ophthalmoplegia. External ophthalmoplegia is further segmented into superior recti, inferior recti, medial recti, lateral recti, inferior oblique, and superior oblique muscles.

On the basis of treatment, the market is segmented into surgery, drug treatment, and others. The surgery is further segmented into strabismus surgery and others.

On the basis of end users, the market is segmented into hospital & clinics, ambulatory clinics, and others.

Regional analysis 

The Americas dominates the global ophthalmoplegia market owing to well-developed technology and increased patient population with eye sight problem primarily due to increasing prevalence of diabetes. Additionally, high healthcare expenditure and the presence of some of the leading players have fuelled the growth of the market in this region.

Europe is the second largest ophthalmoplegia market, which is followed by Asia Pacific. Increasing government support and availability of funds for research drive the growth of the market. Asia Pacific is the fastest growing ophthalmoplegia market due to increasing geriatric population and rapidly developing medical sector.

On the other hand, the Middle East & Africa holds the least share of the market due to limited availability of medical facilities and poor economic and political conditions in Africa.

Key Players 

Some of key players profiled in the report are Abbott (US), Novartis AG (Switzerland), ZEISS International (Germany), Valeant Pharmaceuticals International, Inc. (US), Amritt, Inc. (US), Medline Industries, Inc. (US), ALLERGAN (Ireland), and Johnson & Johnson (US). 

Research Methodology Ophthalmoplegia Market-

The report for the global ophthalmoplegia market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.

Intended Audience

  • Ophthalmic device manufacturers & suppliers

  • Research and development (R&D) companies

  • Hospitals and clinics

  • Academic institutes and universities 

Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   2017-2023: 7.2%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment and End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Abbott (US), Novartis AG (Switzerland), ZEISS International (Germany), Valeant Pharmaceuticals International, Inc. (US), Amritt, Inc. (US), Medline Industries, Inc. (US), ALLERGAN (Ireland), and Johnson & Johnson (US)
  Key Market Opportunities   Rapid developments in technology
  Key Market Drivers

  • Increasing number of people with ophthalmoplegia
  • Increasing geriatric population

  • Frequently Asked Questions (FAQ) :

    Ophtalmoplegia market is predicted to grow at a 7.2% CAGR between 2017-2023.

    The Americas is predicted to lead the ophtalmoplegia market.

    Major end users of the ophtalmoplegia market include ambulatory clinics, hospitals and clinics, and others.

    Key players profiled in the ophtalmoplegia market include Johnson & Johnson (US), ALLERGAN (Ireland), Medline Industries, Inc. (US), Amritt, Inc. (US), Valeant Pharmaceuticals International, Inc. (US), ZEISS International (Germany), Novartis AG (Switzerland), and Abbott (US).

    Availability of cheap alternative treatment and high treatment cost may limit the ophtalmoplegia market growth.

    Brief TOC

    1 Report Prologue

    2 Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    3 Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    4 Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    5. Market Factor Analysis

    5.1 Porters five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain

    5.3 Investment Feasibility Analysis

    5.4 Price Factor Analysis

    6. Global Ophthalmoplegia Market, by Types

    6.1 External ophthalmoplegia

    6.1.1 Superior Recti

    6.1.2 Inferior Recti

    6.1.3 Medial Recti

    6.1.4 Lateral Recti,

    6.1.5 Inferior Oblique

    6.1.6 Superior Oblique Muscles.

    6.2 Internuclear opthalmoplegia

    7. Global Ophthalmoplegia Market, by Treatments

    7.1 Introduction

    7.2 Surgery

    7.2.1 Strabismus Surgery

    7.2.2 Others

    7.3 Drug Treatment

    7.4 Others

    8. Global Ophthalmoplegia Market, by End Users

    8.1 Introduction

    8.2 Hospital & Clinics

    8.3 Ambulatory Clinics

    8.4 Others

    9. Global Ophthalmoplegia Market by Region

    9.1 Introduction

    9.2 North America

    9.2.1 US

    9.2.2 Canada

    9.3 Europe

    9.3.1 Germany

    9.3.2 France

    9.3.3 Italy

    9.3.4 Spain

    9.3.5 UK

    9.3.6 Rest of Europe

    9.4 Asia Pacific

    9.4.1 Japan

    9.4.2 China

    9.4.3 India

    9.4.4 Australia

    9.4.5 Republic of Korea

    9.4.6 Rest of Asia Pacific

    9.5 The Middle East & Africa

    9.5.1 United Arab Emirates

    9.5.2 Saudi Arabia

    9.5.3 Oman

    9.5.4 Kuwait

    9.5.5 Qatar

    9.5.6 Rest of Middle East & Africa

    10 Company Landscape

    10.1 Introduction

    10.2 Market share Analysis

    10.3 Key Development & Strategies

    10.3.1 Key Developments

    11 Company Profiles

    11.1 Abbott

    11.1.1 Company Overview

    11.1.2 Product Overview

    11.1.3 Financials

    11.1.4 SWOT Analysis

    11.2 Novartis AG

    11.2.1 Company Overview

    11.2.2 Product Overview

    11.2.3 Financial Overview

    11.2.4 Key Developments

    11.2.5 SWOT Analysis

    11.3 ZEISS International

    11.3.1 Company Overview

    11.3.2 Product Overview

    11.3.3 Financial Overview

    11.3.4 Key Development

    11.3.5 SWOT Analysis

    11.4 Valeant Pharmaceuticals International, Inc.

    11.4.1 Company Overview

    11.4.2 Product/Business Segment Overview

    11.4.3 Financial Overview

    11.4.4 Key Development

    11.4.5 SWOT Analysis

    11.5 Amritt, Inc.

    11.5.1 Company Overview

    11.5.2 Product Overview

    11.5.3 Financial overview

    11.5.4 Key Developments

    11.6 Medline Industries, Inc.

    11.6.1 Company Overview

    11.6.2 Product Overview

    11.6.3 Financial Overview

    11.6.4 Key Developments

    11.7 ALLERGAN.

    11.7.1 Overview

    11.7.2 Product Overview

    11.7.3 Financials

    11.7.4 Key Developments

    11.7.5 SWOT Analysis

    11.8 Others

    12 MRFR Conclusion

    12.1 Key Findings

    12.1.1 From CEO’s View Point

    12.1.2 Unmet Needs of the Market

    12.2 Key Companies to Watch

    12.3 Prediction of Ophthalmic Industry

    13 Appendix